PCSK9 Education and Research Forum: Newsletter - August 2014
Looking to ESC Congress 2014: what will be hot for PCSK9 Research?
| • |
ESC Hotlines: ODYSSEY Combo II, ODYSSEY FH I and FH II |
|
| • |
ESC discusses innovations in lipid-lowering therapy: PCSK9 features high on the list |
|
| • |
Focus on heterozygous FH: who are these patients and why do they matter? |
|
| • |
New frontiers for the high-risk patient |
|
And much more… Join PCSK9 Forum for the latest live coverage
From the Editors
Implementing Models of Care in FH – the real challenge ahead
Prof. Gerald F. Watts, Perth, Australia makes the case
Hot Topics
IMPROVE-IT: Will it prove anything?
Prof. Anthony S. Wierzbicki, London, UK adds to debateSend an invitation to join PCSK9 Forum to your colleagues, click here for the invite linkOur mission
Our goal
The PCSK9 Education and Research Forum is the major, globally-recognised resource of independent, scientific knowledge of the critical importance of PCSK9 inhibition in the search for treatments which promise to transform the prognosis of millions of people with hypercholesterolaemia and accelerated atherosclerotic vascular disease.
Our response to this challenge
Established by leading researchers as a not-for-profit organisation, the PCSK9 Education and Research Forum will provide healthcare professionals with open access to electronic and multimedia platforms providing real-time reporting of significant developments and news; authoritative analysis and commentary; and, an extensive library of accredited educational materials tailored to the differing needs of a spectrum of audiences. As a result, the Forum will expand awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.
Our partnership and outreach
Through its unique global network of researchers and clinicians, the PCSK9 Education and Research Forum will reach out to academic institutions, research organisations and societies which share the Forum’s commitment to the reduction of CVD mortality and morbidity through improved management of atherosclerotic dyslipidaemia. The Forum will establish educational partnerships with such organisations through jointly sponsored symposia as well as accredited research and educational programmes. |
|
|
